Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
One hundred and twenty-six cases of nodular lymphoma have been classified cytologically by the criteria of Rappaport, and have been divided into three architectural groups, based on the degree of nodularity. Eighty-five percent of the patients have been followed for at least 5 years after initial therapy. Analysis of actuarial survival curves reveals that patients in the poorly differentiated lymphocytic and mixed histiocytic-lymphocytic categories with the three architectural patterns ("nodular only," "nodular with focal diffuse," and "nodular with diffuse") have similar long-term and disease-free survivals. Nevertheless, any degree of nodularity imparts a more favorable prognosis than diffuse lymphoma of coreresponding cell type. In the small number of patients with a nodular lye than in the other two histiocytic type, associated with diffuse areas, the prognosis is less favorable than in the other two histologic groups. Thus, a nodular lymphoma of so-called histiocytic type with diffuse areas may behave more like a diffuse than nodular lymphoma, and warrants appropriate therapy.
View details for Web of Science ID A1977DX06500035
View details for PubMedID 332322